Retatrutide vs Semaglutide: Comparing Two Different Stages of Development

Step 1, Understand what each medicine actually does

Semaglutide targets a single receptor: GLP-1. By activating it, the medicine slows how quickly the stomach empties and signals the brain to reduce hunger. It's a well-characterised mechanism backed by years of data, and the NHS medicine page for semaglutide describes the pharmacology and side-effect profile in patient-friendly terms.

Retatrutide is different in architecture. It acts on three receptors simultaneously: GLP-1, GIP and glucagon. That triple-agonist design is what makes it scientifically interesting, and also what makes it harder to predict how it will behave across a broad population over years rather than months. No triple-agonist medicine has yet received a UK marketing authorisation for any indication. The mechanism is promising; promising is not the same as proven at scale.

It's worth knowing that tirzepatide (the active ingredient in Mounjaro) already works on two of those three pathways (GLP-1 and GIP), and it is fully licensed in the UK. You can read more about the structural differences between retatrutide and semaglutide if the mechanism detail matters to you.

Step 2 (Look at what the trial numbers actually say (and what they don't)

Phase 2 trial results for retatrutide, published in the New England Journal of Medicine, reported average weight reductions of around 17–24% over 48 weeks depending on dose) figures that generated considerable excitement. For context, the STEP 1 trial for semaglutide 2.4mg reported an average of roughly 15% body-weight reduction over 68 weeks, as published in the NEJM. Retatrutide's highest-dose numbers sit above that.

But phase 2 is a safety and dose-finding study, typically involving a few hundred participants over less than a year. It cannot answer questions about long-term cardiovascular outcomes, rare adverse events or what happens when a much wider population takes the medicine. Semaglutide has walked that longer road, years of phase 3 trials, regulatory review, post-market surveillance and real-world use. That depth of evidence is what a licensing authority weighs, not a headline percentage.

The table above reflects the current position. It will change as retatrutide's phase 3 programme completes and regulators review the full dataset.

Step 3 (Consider what the licensing gap means in practice

We hear from people who feel frustrated by waiting) frustrated that a medicine showing strong early numbers isn't available yet, or that the NHS criteria feel out of reach. That's a reasonable thing to feel. Clinical trial timelines and regulatory processes are slow by design, and that slowness can feel like a barrier when you're ready to act now.

The practical reality is that retatrutide cannot legally be prescribed in the UK for weight management at the moment. Websites offering it are not operating within the licensed UK supply chain, and the MHRA has been clear about the risks of medicines sourced outside that chain. If you're thinking about what a switch might look like when retatrutide does reach the market, the considerations around moving between treatments are worth reading early.

Semaglutide under the Wegovy brand is the established, regulator-approved option for weight management right now. NICE's appraisal of semaglutide (TA875) sets out the evidence base and the conditions under which it is recommended. For people whose BMI and clinical picture fall within the licensed criteria, it is a medicine with a known profile, not a placeholder while something better arrives.

There is also the question of whether semaglutide is the right starting point at all. How supplements like berberine compare to licensed medicines is a question people ask early in the process, and it's worth having a clear answer before committing to any treatment path.

Step 4, What this means for a decision today

If you're weighing up these two medicines because you want the most effective option available, the honest framing is this: semaglutide has the evidence, the licence and the infrastructure; retatrutide has the early promise and the ongoing trials. They're not interchangeable options at this moment, they're at different stages of a long process. Anyone wanting a detailed side-by-side breakdown can find a thorough look at how retatrutide compares to Wegovy across the factors that matter most to people making this decision.

Which treatment suits your situation is a clinical decision. Your prescriber will look at your BMI, your health history, any medicines you already take and what your goals are. That's not a box-ticking exercise, it shapes which medicine, which starting dose and which monitoring plan makes sense for you specifically. If you'd like to explore whether Wegovy or another licensed treatment is appropriate, our prescribers are available to review your consultation the same day. You can also read more about whether retatrutide's early data makes it objectively better than semaglutide, the answer is more nuanced than the headlines suggest.

When retatrutide reaches a UK licence, the comparison will be worth revisiting with full phase 3 data in hand. Until then, the evidence base sits firmly with semaglutide for anyone who is eligible and ready to start.